



Cala Health Announces Expansion of Executive Team with Steve Higa and Greg Schulte

- *Adding Deep Strategic Experience, Operational Excellence and Passion for Innovative Design to the Cala Health leadership team*

Burlingame, CA – June 7, 2021 -- Cala Health, Inc., a bioelectronic medicine company developing wearable therapies for chronic disease, today announces an expansion of the executive team with medical technology industry veterans Steve Higa as Vice President, Manufacturing & Quality and Greg Schulte as Vice President, Hardware.

“The additions of these seasoned professionals, Steve and Greg, to our team supports the current on-market Cala Trio device and expands our capabilities for our pipeline of future products in development to treat conditions using electricity as medicine,” said Renee Ryan, Chief Executive Officer, Cala Health.

Mr. Steve Higa has held numerous manufacturing, operational, and engineering roles in Silicon Valley. Prior to joining Cala Health, Mr. Higa worked as Vice President, Manufacturing for miraDry and held a VP, Operations role for Zoll Circulation. He holds an M.S. in Electrical Engineering from Santa Clara University.

Greg Schulte has 20 years of experience in product strategy, design, and engineering for companies and clients of all sizes focused in medical, utility, and consumer electronics. A mechanical engineer by training, Mr. Schulte cofounded Guide Medical Ventures in 2011, managing strategic vision and technology for a portfolio of 6 start-ups in the medical device space. Prior to joining Cala Health, Mr. Schulte led engineering at Mindtribe, a boutique hardware development consultancy acquired by Accenture. Mr. Schulte started his career at Medtronic as a mechanical design engineer in neuromodulation and honed his engineering leadership at Intellect Medical (acquired by Boston Scientific), Enpath Medical and EnteroMedics.

About Cala Health

Cala Health Inc., an award-winning bioelectronic medicine company headquartered in the San Francisco Bay area, is transforming the standard of care for chronic disease. The Company’s wearable neuromodulation therapies utilize electricity as medicine, merging innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation, while its vertically integrated commercial model is transforming the delivery of prescription therapies. Cala Health’s lead product, [Cala Trio™](#), is the only non-invasive, wrist-worn prescription therapy currently available for essential tremor. Cala Health has new therapies under development in neurology, cardiology, and mental health and is backed by leading investors in both healthcare and technology. For more information, visit [CalaHealth.com](#).

Contact

Erich Sandoval

Erich.Sandoval@FinnPartners.com

+1 917 497 2867